Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shun Lu

Showing results (561-570 of 661) with videos related to

Pageof 67
Sort By:
The Lancet Regional Health. Western Pacific|January 6, 2025
Consensus on the lung cancer management after third-generation EGFR-TKI resistanceQing Zhou, Hongyun Zhao, Shun Lu, et al.
The Lancet. Respiratory Medicine|June 2, 2020
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trialYi-Long Wu, Ying Cheng, Jianying Zhou, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancerKeunchil Park, Jaafar Bennouna, Michael Boyer, et al.
The Lancet. Oncology|July 26, 2011
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Yi-Long Wu, Gongyan Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|September 13, 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trialMartin Reck, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
The Journal of Clinical Investigation|May 2, 2022
Loss of the collagen IV modifier prolyl 3-hydroxylase 2 causes thin basement membrane nephropathyHande Aypek, Christoph Krisp, Shun Lu, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|December 10, 2015
The Calcium-Binding Protein S100A6 Accelerates Human Osteosarcoma Growth by Promoting Cell Proliferation and Inhibiting Osteogenic DifferentiationYasha Li, Eric R Wagner, Zhengjian Yan, et al.
The Lancet. Respiratory Medicine|September 22, 2025
Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised studyShun Lu, Oleksandr Vynnychenko, Yaroslav Kulyaba, et al.
JAMA Oncology|June 15, 2018
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical TrialGlenwood D Goss, Enriqueta Felip, Manuel Cobo, et al.
Scientific Reports|December 8, 2015
Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian cancer cellsYoulin Deng, Junhui Zhang, Zhongliang Wang, et al.
Pageof 67

Showing results (561-570 of 661) with videos related to

Sort By:
Pageof 67
The Lancet Regional Health. Western Pacific|January 6, 2025
Consensus on the lung cancer management after third-generation EGFR-TKI resistanceQing Zhou, Hongyun Zhao, Shun Lu, et al.
The Lancet. Respiratory Medicine|June 2, 2020
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trialYi-Long Wu, Ying Cheng, Jianying Zhou, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancerKeunchil Park, Jaafar Bennouna, Michael Boyer, et al.
The Lancet. Oncology|July 26, 2011
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Yi-Long Wu, Gongyan Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|September 13, 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trialMartin Reck, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
The Journal of Clinical Investigation|May 2, 2022
Loss of the collagen IV modifier prolyl 3-hydroxylase 2 causes thin basement membrane nephropathyHande Aypek, Christoph Krisp, Shun Lu, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|December 10, 2015
The Calcium-Binding Protein S100A6 Accelerates Human Osteosarcoma Growth by Promoting Cell Proliferation and Inhibiting Osteogenic DifferentiationYasha Li, Eric R Wagner, Zhengjian Yan, et al.
The Lancet. Respiratory Medicine|September 22, 2025
Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised studyShun Lu, Oleksandr Vynnychenko, Yaroslav Kulyaba, et al.
JAMA Oncology|June 15, 2018
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical TrialGlenwood D Goss, Enriqueta Felip, Manuel Cobo, et al.
Scientific Reports|December 8, 2015
Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian cancer cellsYoulin Deng, Junhui Zhang, Zhongliang Wang, et al.
Pageof 67